Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Naloxone/oxycodone - Mundipharma

Drug Profile

Naloxone/oxycodone - Mundipharma

Alternative Names: OXN PR; Oxycodone hydrochloride/naloxone hydrochloride - Mundipharma; Oxycodone/naloxone extended release - Mundipharma; Oxycodone/naloxone prolonged release - Mundipharma; Targin; Targinact; Targiniq; Targiniq ER

Latest Information Update: 02 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mundipharma GmbH
  • Developer Mundipharma GmbH; Purdue Pharma
  • Class Antidotes; Morphinans; Morphine derivatives; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid delta receptor agonists; Opioid kappa receptor agonists; Opioid mu receptor agonists; Opioid mu receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Constipation; Pain; Restless legs syndrome
  • Phase II Interstitial cystitis

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 15 Jun 2018 Chemical structure information added
  • 30 Mar 2017 Mundipharma completes a phase III trial in Pain (non-cancer) in China (PO) (NCT01918098)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top